- Home
- NGNE vs NPCT Comparison
NGNE vs NPCT Comparison
Compare NGNE & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- NPCT
- Stock Information
- Founded
- NGNE 2003
- NPCT 2020
- Country
- NGNE United States
- NPCT United States
- Employees
- NGNE N/A
- NPCT N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- NGNE Health Care
- NPCT Finance
- Exchange
- NGNE Nasdaq
- NPCT Nasdaq
- Market Cap
- NGNE 325.3M
- NPCT 314.6M
- IPO Year
- NGNE N/A
- NPCT N/A
- Fundamental
- Price
- NGNE $18.48
- NPCT $10.91
- Analyst Decision
- NGNE Strong Buy
- NPCT
- Analyst Count
- NGNE 7
- NPCT 0
- Target Price
- NGNE $41.86
- NPCT N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- NPCT 107.1K
- Earning Date
- NGNE 08-11-2025
- NPCT 01-01-0001
- Dividend Yield
- NGNE N/A
- NPCT 9.82%
- EPS Growth
- NGNE N/A
- NPCT N/A
- EPS
- NGNE N/A
- NPCT N/A
- Revenue
- NGNE N/A
- NPCT N/A
- Revenue This Year
- NGNE N/A
- NPCT N/A
- Revenue Next Year
- NGNE N/A
- NPCT N/A
- P/E Ratio
- NGNE N/A
- NPCT N/A
- Revenue Growth
- NGNE N/A
- NPCT N/A
- 52 Week Low
- NGNE $6.88
- NPCT $8.58
- 52 Week High
- NGNE $74.49
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- NPCT 48.99
- Support Level
- NGNE $19.59
- NPCT $10.82
- Resistance Level
- NGNE $20.46
- NPCT $10.98
- Average True Range (ATR)
- NGNE 1.23
- NPCT 0.12
- MACD
- NGNE -0.20
- NPCT -0.01
- Stochastic Oscillator
- NGNE 13.37
- NPCT 48.15
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.